Anzeige
Mehr »
Samstag, 28.02.2026 - Börsentäglich über 12.000 News
Hochgradiger Fund in Kanada: Steht dieser Rohstoff-Explorer vor der Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

NASDAQ Biotech 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im NASDAQ Biotech

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
02:18Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange2
00:00Ascendis Pharma: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older2
FrHarrow Health Q4 2025 Earnings Preview3
FrDisc Medicine undergoes restructuring plan; slashes 20% of workforce4
FrTectonic Therapeutic, Inc. - S-8, Securities to be offered to employees in employee benefit plans4
FrAnalyst Bullish on Cogent (COGT) Amid Expected Drug Approval2
FrCiti, Stifel Bullish on Olema (OLMA) Despite COO Departure3
FrP/E Ratio Insights for Gilead Sciences4
FrWhat Analysts Are Saying About CG Oncology Stock1
FrAdaptive Biotechnologies Corp - S-8, Securities to be offered to employees in employee benefit plans1
FrPROTHENA CORP PUBLIC LTD CO - 8-K, Current Report1
FrProthena authorizes $100 million share buyback program1
FrNovocure to Participate in 2026 Leerink Global Healthcare Conference182Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 10, 2026. Frank Leonard, Chief Executive Officer, and Christoph...
► Artikel lesen
FrProthena kündigt Aktienrückkaufprogramm über 100 Mio. US-Dollar an1
FrProthena authorizes up to $100 million share repurchase plan4
FrAardvark Therapeutics, Inc. - 8-K, Current Report1
FrAmneal Pharmaceuticals, Inc. - 10-K, Annual Report1
FrProthena Corporation plc: Prothena Announces up to $100 Million Share Repurchase Plan203Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
► Artikel lesen
FrAardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome1
FrPROTHENA CORP PUBLIC LTD CO - 10-K, Annual Report2
Weiter >>